Targeted delivery of rifampicin to tuberculosis-infected macrophages: design, in-vitro, and in-vivo performance of rifampicin-loaded poly(ester amide)s nanocarriers

International Journal of Pharmaceutics

Volumn 513, Issue 1-2, 2016, Pages 628-635

  Amarnath Praphakar, Rajendran ^a   Munusamy, Murugan A ^b   Sadasivuni, Kishor Kumar ^c   Rajan, Mariappan ^a  

^a MADURAI KAMARAJ UNIVERSITY   (India)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c QATAR UNIVERSITY   (Qatar)

Author keywords

Alveolar macrophages; Mycobacterium smegmatis; Nanoparticles; Polyesteramides; Rifampicin; Tuberculosis

Indexed keywords

NANOCARRIER; POLY(ESTER AMIDE); RIFAMPICIN; UNCLASSIFIED DRUG; AMIDE; DRUG CARRIER; NANOPARTICLE; POLYESTER; TUBERCULOSTATIC AGENT;

ANTIBACTERIAL ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DIALYSIS; DIALYSIS MEMBRANE; DRUG RELEASE; FLUORESCENCE MICROSCOPY; HYDROGEN BOND; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; LUNG ALVEOLUS MACROPHAGE; MYCOBACTERIUM SMEGMATIS; NANOENCAPSULATION; NANOFABRICATION; PARTICLE SIZE; POLYMERIZATION; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY; TUBERCULOSIS; X RAY DIFFRACTION; ZETA POTENTIAL; ANIMAL; CELL LINE; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; MACROPHAGE; MICROBIOLOGY; MYCOBACTERIUM; RAT; ULTRASTRUCTURE;

AMIDES; ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; CELL LINE; DRUG CARRIERS; DRUG DESIGN; DRUG LIBERATION; MACROPHAGES; MICROSCOPY, ELECTRON, SCANNING; MYCOBACTERIUM; NANOPARTICLES; POLYESTERS; RATS; RIFAMPIN;

EID: 84988917003     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2016.09.080     Document Type: Article

References (32)

1. Ahmad, Z., Zahoor, A., Sharma, S., Khuller, G.K., Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int. J. Antimicrob. Agents 26 (2005), 298–303.
2. Alifano, P., Palumbo, C., Pasanisi, D., Talà, A., Rifampicin-resistance, rpoB polymorphism and RNA polymerase genetic engineering. J. Biotechnol. 202 (2015), 60–77.
3. Anisimova, Y.V., Gelperina, S.I., Peloquin, C.A., Heifets, L.B., Nanoparticles as antituberculosis drugs carriers: effect on activity against Mycobacterium tuberculosis in human monocyte-derived macrophages. J. Nanopart. Res. 2 (2000), 165–171.
4. Baker, R., Controlled Release of Biologically Active Agents. 1987, Academic Press, New York.
5. Barrow, E.L., Winchester, G.A., Staas, J.K., Quenelle, D.C., Barrow, W.W., Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis—infected macrophages. Antimicrob. Agents Chemother. 42 (1998), 2682–2689.
6. Cao, P., Bae, Y., Polymer nanoparticulate drug delivery and combination cancer therapy. Future Oncol. 8 (2012), 1471–1480.
7. Chaubey, P., Mishra, B., Mannose-conjugated chitosan nanoparticles loaded with rifampicin for the treatment of visceral leishmaniasis. Carbohydr. Polym. 101 (2014), 1101–1108.
8. Dube, D., Agrawal, G.P., Vyas, S.P., Tuberculosis, from molecular pathogenesis to effective drug carrier design. Drug Discov. Today 17 (2012), 760–773.
9. Dutt, M., Khuller, G.K., Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in poly(d l lactide-co-glycolide) microparticles. J. Antimicrob. Chemother. 47 (2001), 829–835.
10. Errico, C., Bartoli, C., Chiellini, F., Chiellini, E., Poly (hydroxyalkanoates)-based polymeric nanoparticles for drug delivery. J. Biomed. Biotechnol., 10, 2009.
11. Fan, Y., Kobayashi, M., Kise, H., Synthesis and biodegradability of new polyesteramides containing peptide linkages. J. Polym. 32:10 (2000), 817–822.
12. Fan, Y., Kobayashi, M., Kise, H., Synthesis and specific biodegradation of novel polyesteramides containing amino acid residues. J. Polym. Sci. A Polym. Chem. 39 (2001), 1318–1328.
13. Gumbo, T., Louie, A., Deziel, M.R., Liu, W., Parsons, L.M., Salfinger, M., Drusano, D.L., Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob. Agents Chemother. 51 (2007), 3781–3788.
14. Guo, K., Chu, C.C., Chkhaidze, E., Katsarava, R., Synthesis and characterization of novel biodegradable unsaturated poly(ester amide)s. J. Polym. Sci. A Polym. Chem. 43 (2005), 1463–1477.
15. Hartmann, G., Honikel, K.O., Knüseland, F., Nüesch, J., The specific inhibition of the DNA-directed RNA synthesis by rifamycin. Biochim. Biophys. Acta. 145 (1967), 843–844.
16. Labuschagne, P.W., Adami, R., Liparoti, S., Naidoo, S., Swai, H., Reverchon, E., Preparation of rifampicin/poly (D, L-lactide) nanoparticles for sustained release by supercritical assisted atomization technique. J. Supercrit. Fluids. 95 (2014), 106–117.
17. Li, P., Wang, Y., Peng, Z., She, F., Kong, L., Development of chitosan nanoparticles as drug delivery systems for 5-fluorouracil and leucovorin blends. Carbohydr. Polym. 85 (2011), 698–704.
18. Lopes, C.M., Bettencourt, C., Rossi, A., Buttini, F., Barata, P., Overview on gastroretentive drug delivery system for improving drug bioavailability. Int. J. Mol. Pharm. 510:1 (2016), 144–158.
19. Maretti, E., Rossi, T., Bondi, M., Croce, M.A., Hanuskova, M., Leo, E., Sacchetti, F., Iannuccelli, V., Inhaled Solid Lipid Microparticles to target alveolar macrophages for tuberculosis. Int. J. Mol. Pharm. 462:1–2 (2014), 74–82 (28).
20. Mathiowitz, E., Encyclopedia of Controlled Drug Delivery. 1999, Wiley-Inter, New York.
21. Mehta, S.K., Jindal, N., Formulation of Tyloxapol niosomes for encapsulation, stabilization and dissolution of anti-tubercular drugs. Colloids Surf. B Biointerfaces 101 (2013), 434–441.
22. Pham, D.D., Fattal, E., Tsapis, N., Pulmonary drug delivery systems for tuberculosis treatment. Int. J. Mol. Pharm. 478:2 (2015), 517–529.
23. Rajan, M., Raj, V., Encapsulation characterisation and in-vitro release of anti-tuberculosis drug using chitosan–poly ethylene glycol nanoparticles. Int. J. Pharm. Pharm. Sci. 4 (2012), 255–259.
24. Rajan, M., Raj, V., Formation and characterization of chitosan-polylacticacid-polyethyleneglycol-gelatinnanoparticles A novel biosystem for controlled drug delivery. Carbohydr. Polym. 98 (2013), 951–958.
25. Roberts, R.M., Gilbert, J.C., Rodewald, L.B., Wingrove, A.S., Modern Experimental Organic Chemistry. 4th ed., 1985, Saunders, Fort Worth, 717.
26. Saraogi, G.K., Gupta, P., Gupta, D., Jain, N.K., Agrawal, G.P., Gelatin nanocarriers as potential vectors for effective management of tuberculosis. Int. J. Pharm. 385 (2010), 143–149.
27. Shivshankar, R.M., Dinda, H., Sathyan, A., Sarma, J.D., Shunmugam, R., Increased Bioavailability of Rifampicin from stimuli-responsive smart nano carrier. Appl. Mater. Interfaces 6 (2014), 16895–16902.
28. Singh, S., Mariappan, T.T., Sharda, N., Kumar, S., Chakraborti, A.K., The reason for an increase in decomposition of rifampicin in the presence of isoniazid under acid conditions. Pharm. Pharmacol. Commun. 6 (2000), 405–410.
29. Singh, H., Jindal, S., Singh, M., Sharma, G., Kaur, I.P., Nano-formulation of rifampicin with enhanced bioavailability: development, characterization and in-vivo safety. Int. J. Mol. Pharm. 485:1–2 (2015), 138–151.
30. Smitha, K.T., Nisha, N., Maya, S., Biswasand, R., Jayakumar, R., Delivery of rifampicin-chitin nanoparticles into the intracellular compartment of polymorphonuclear leukocytes. Int. J. Biol. Macromol. 74 (2015), 36–43.
31. Steele, M.A., Burk, R.F., DesPrez, R.M., Toxic hepatitis with isoniazid and rifampin: a meta-analysis. Chest 99 (1991), 465–471.
32. Ulbrich, K., Subr, V., Polymeric anticancer drugs with pH controlled activation. Adv. Drug Deliv. Rev. 56 (2004), 1023–1050.